305 related articles for article (PubMed ID: 37667136)
1. Emerging diagnostics and therapeutics for Alzheimer disease.
Self WK; Holtzman DM
Nat Med; 2023 Sep; 29(9):2187-2199. PubMed ID: 37667136
[TBL] [Abstract][Full Text] [Related]
2. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Mullane K; Williams M
Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer Disease.
McDade EM
Continuum (Minneap Minn); 2022 Jun; 28(3):648-675. PubMed ID: 35678397
[TBL] [Abstract][Full Text] [Related]
6. Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications.
Gonzalez-Ortiz F; Kac PR; Brum WS; Zetterberg H; Blennow K; Karikari TK
Mol Neurodegener; 2023 Mar; 18(1):18. PubMed ID: 36927491
[TBL] [Abstract][Full Text] [Related]
7. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
Gavrilova SI
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
[TBL] [Abstract][Full Text] [Related]
8. Applied multimodal diagnostics in a case of presenile dementia.
Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
[TBL] [Abstract][Full Text] [Related]
9. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Alzheimer's Disease.
Guzman-Martinez L; Maccioni RB; Farías GA; Fuentes P; Navarrete LP
Curr Alzheimer Res; 2019; 16(6):518-528. PubMed ID: 31099321
[TBL] [Abstract][Full Text] [Related]
11. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
13. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis.
Rostamzadeh A; Bohr L; Wagner M; Baethge C; Jessen F
Neurology; 2022 Oct; 99(17):e1866-e1874. PubMed ID: 36028322
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer Disease.
Apostolova LG
Continuum (Minneap Minn); 2016 Apr; 22(2 Dementia):419-34. PubMed ID: 27042902
[TBL] [Abstract][Full Text] [Related]
16. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
17. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
[TBL] [Abstract][Full Text] [Related]
18. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
[TBL] [Abstract][Full Text] [Related]
19. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
